Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Shares
-
Shares outstanding
-
124,058,172
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
54,883,537
-
Shares change
-
+1,083,956
-
Total reported value, excl. options
-
$172,881,709
-
Value change
-
+$3,394,419
-
Put/Call ratio
-
38%
-
Number of buys
-
48
-
Number of sells
-
-24
-
Price
-
$3.15
Significant Holders of ADC Therapeutics SA - Common Shares (ADCT) as of Q3 2024
95 filings reported holding ADCT - ADC Therapeutics SA - Common Shares as of Q3 2024.
ADC Therapeutics SA - Common Shares (ADCT) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 54,883,537 shares
of 124,058,172 outstanding shares and own 44% of the company stock.
Largest 10 shareholders include Redmile Group, LLC (15,669,217 shares), Prosight Management, LP (9,636,237 shares), ORBIMED ADVISORS LLC (4,533,801 shares), BlackRock, Inc. (4,399,134 shares), MORGAN STANLEY (3,040,794 shares), BANK OF AMERICA CORP /DE/ (2,497,940 shares), SILVERARC CAPITAL MANAGEMENT, LLC (1,795,080 shares), GOLDMAN SACHS GROUP INC (1,688,594 shares), PLATINUM INVESTMENT MANAGEMENT LTD (1,444,516 shares), and Siren, L.L.C. (1,163,461 shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.